Spondyloarthropathies

Spondyloarthropathies — Internal Medicine

How it begins

Análisis integral de las espondiloartropatías seronegativas: fisiopatología, criterios diagnósticos ASAS, manifestaciones axiales y periféricas, extraarticulares, imagenología avanzada y terapéutica biológica basada en evidencia.

What it covers

1. ASAS Concept and Classification
2. · ASAS Classification Current
3. · The Continuous Spectrum of SpA
4. Pathogenesis and Immunopathology
5. · HLA-B27: Pathogenic Mechanisms
6. · The IL-23 / IL-17 Axis: Central Engine of the SpA
7. · Genetics: Beyond HLA-B27
8. · Intestine–Joint–Microbiome Axis
9. Common Clinical Manifestations of SpA
10. · Inflammatory Lumbar Pain (ILP)
11. · Enthesitis
12. · Peripheral Arthritis
13. · Dactylitis
14. · Extra-articular Manifestations (MEA) of SpA
15. Ankylosing spondylitis (AS)
16. · Detailed Clinical Picture
17. · Activity and Function Indices in EA
18. Non-Radiographic Axial SpA (nr-axSpA)
19. · ASAS 2009 Criteria for SpA Axial
20. · nr-axSpA vs. EA: Continuous or Different Entities?
21. Psoriatic Arthritis (PsA)
22. · CASPAR 2006 Criteria
23. · Clinical Patterns of PsA (Moll and Wright Classification)
24. · Detailed Musculoskeletal Manifestations
25. · Minimal Skin Disease — Arthritis without Visible Psoriasis?
26. Reactive Arthritis
27. · Trigger Microorganisms
28. · Clinical Picture: The Reiter Triad and Beyond
29. · Diagnosis and Evolution
30. Enteropathic arthropathy
31. · Orchard Classification: Two Types of Peripheral Arthropathy
32. · Axial arthropathy in IBD
33. AIJ ERA and SpA Juvenil
34. · Distinctive Characteristics in the Pediatric Context
35. Diagnostic Criteria and Classification
36. · Diagnostic Algorithm for Chronic Low Back Pain in Young Adults
37. · ASAS Criteria for SpA Periférica 2011
38. Laboratory and Imaging
39. · Laboratory in the SpA
40. · Conventional Radiology in SpA
41. · Magnetic Resonance (MRI) — Standard for Early Diagnosis
42. · Musculoskeletal Ultrasound (MUS)
43. Treatment: Principles and Conventional Drugs
44. · General Principles of Treatment
45. · AINEs — First Line at SpA Axial
46. · Conventional DMARDS (csDMARDS) — Limited Efficacy in Axial Affectation
47. Biological Therapy and JAK Inhibitors
48. · Indications for Starting Biological Therapy in Axial SpA
49. · TNF-α inhibitors (anti-TNF)
50. · IL-17A inhibitors (anti-IL-17A)
51. · IL-12/23 inhibitors (anti-p40)
52. · Selective IL-23 inhibitors (anti-p19)
53. · JAK inhibitors (JAKi)
54. Special Situations
55. · Pregnancy and SpA
56. · Vaccinations in Patients with SpA in Biological Therapy
57. · Surgery in Patients with SpA and Biologicals
58. Monitoring, Comorbidities and Prognosis
59. · Disease Activity Monitoring
60. · Prevalent Comorbidities in SpA
61. · Prognostic Factors in SpA